Actively Recruiting
A Phase 3 Study to Reduce Mortality in Adults With Advanced HIV Using Azithromycin Prophylaxis Compared to Placebo
Led by Population Health Research Institute · Updated on 2025-09-03
8000
Participants Needed
52
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether taking azithromycin as a preventive treatment can reduce the risk of death in adults with advanced HIV disease. This is a Phase 3, double-blind, placebo-controlled trial involving multiple centers. The study aims to understand if azithromycin prophylaxis can lower mortality compared to a placebo in this vulnerable population. Participants will be randomly assigned to receive either an oral azithromycin tablet or a matching placebo tablet once daily for 28 days. After this treatment period, they will be followed for 24 weeks to measure the main outcome of all-cause mortality. The total study participation will last 48 weeks to monitor both short-term and longer-term effects. During the study, participants will undergo assessments to track survival and hospitalizations at 12 and 24 weeks after starting the treatment. Researchers will closely monitor health outcomes and any hospital stays to evaluate the impact of azithromycin prophylaxis. Safety and adherence will be followed throughout the trial to ensure accurate measurement of results.
CONDITIONS
Brief Title
Reducing Mortality in Adults With Advanced HIV Disease (REVIVE)
Research Team
R
REVIVE Study Coordinator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here